GB Sciences Resets: Exclusive Executive Interview with CFN Media

SEATTLE, WA--(Marketwired - Jan 23, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article and interview discussing recent developments and the path forward for GB Sciences Inc. (OTCQB: GBLX).

GB Sciences recently completed a pivot away from developing agricultural technologies and toward medical marijuana cultivation and cannabinoid biopharmaceutical development. By doing so, the company aims to generate near-term revenue to help offset the cost of developing cannabinoid-based biopharmaceuticals.

In an exclusive interview, CFN Media discussed the company's transition and objectives moving forward with President & CEO John Poss.

GB Sciences believes that cannabinoid-based biopharmaceuticals represent the largest opportunity for the industry. Under the leadership of Chief Science Officer Dr. Andrea Small-Howard, the company has already filed the first of several patents covering complex cannabinoid-containing mixtures capable of enhancing dopamine secretion and protecting neurons from mitochondria-induced free radical damage from neurological disorders.

GB Sciences plans to mitigate the costs of drug development by generating near-term cash flow from the sale of medical marijuana. Recently, the company opened its Las Vegas production facility and anticipates generating initial revenue this quarter. The company also acquired two other Nevada licenses that will be folded into the production facility and expand the scope of its business to include oil extraction/production and other services.

The company hopes to expand its footprint throughout the United States. Currently, the team is actively applying for a cultivation and production license in California that it hopes to secure within the next 12 months. Other opportunities are being explored in Texas, Pennsylvania, and Florida.

Please follow the link to see the interview and read the full article: http://www.cannabisfn.com/gb-sciences-resets-licensed-cultivator-and-biopharma/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.